AstraZeneca’s CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
In a Reuters report, AstraZeneca Plc's (NASDAQ:
Sorrento Shares Pop After Interim Data From Lung Cancer Trial
Sorrento Therapeutics Inc (NASDAQ: SRNE) announced positive results from a pivotal study of Abivertinib on 209 response evaluable, heavily pretreated NSCLC patients by an IRC assessment with matured long-term follow-up data.
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
AstraZeneca Plc (NASDAQ:AZN) has filed suit against former VP and head of investor relations Chris Sheldon as he prepares…
Recap Of Tuesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Amphastar’s (NASDAQ:AMPH) New Drug Application (ND”) for Epinephrine injection…
FDA Accepted Submission of Supplemental New Drug Application for LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration-Resistant Prostate Cancer and Grants Priority Review
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S.
AstraZeneca Announced Lynparza in Combination with Abiraterone Granted Priority Review in the US for Patients with Metastatic Castration-resistant Prostate Cancer
AstraZeneca's supplemental New Drug Application (sNDA) for Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone has been accepted and granted Priority Review in the US for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC).
Lynparza is being jointly developed and commercialised by AstraZeneca and MSD.
AstraZeneca Announced Enhertu Significantly Delayed Disease Progression in DESTINY-Breast02 Phase III Trial vs. Physician’s Choice of Treatment in Patients with HER2-positive Metastatic Breast Cancer
Positive high-level results from the DESTINY-Breast02 Phase III trial of Enhertu (trastuzumab deruxtecan) versus physician's choice of treatment showed the trial met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated wi
Recap Of Friday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line results from its pivotal U.S. Phase 3 study in infants evaluating its 20-valent…
Daiichi-AstraZeneca’s Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
The FDA has approved Daiichi Sankyo (OTC:DSNKY) and AstraZeneca plc’s (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer (NSCLC)…